1887

Abstract

Human immunodeficiency virus type 1 (HIV-1) viral protein R (Vpr) is an accessory protein that interacts with a number of cellular and viral proteins. The functions of many of these interactions in the pathogenesis of HIV-1 have been identified. Deletion of the gene reduces the virulence of HIV-1 dramatically, indicating the importance of this protein for the virus. This review describes the current findings on several established functions of HIV-1 Vpr and some possible roles proposed for this protein. Because Vpr exploits cellular proteins and pathways to influence the biology of HIV-1, understanding the functions of Vpr usually involves the study of cellular pathways. Several functions of Vpr are attributed to the virion-incorporated protein, but some of them are attributed to the expression of Vpr in HIV-1-infected cells. The structure of Vpr may be key to understanding the variety of its interactions. Due to the critical role of Vpr in HIV-1 pathogenicity, study of the interactions between Vpr and cellular proteins may help us to understand the mechanism(s) of HIV-1 pathogenicity.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.011726-0
2009-08-01
2019-11-12
Loading full text...

Full text loading...

/deliver/fulltext/jgv/90/8/1795.html?itemId=/content/journal/jgv/10.1099/vir.0.011726-0&mimeType=html&fmt=ahah

References

  1. Agostini, I., Navarro, J. M., Rey, F., Bouhamdan, M., Spire, B., Vigne, R. & Sire, J. ( 1996; ). The human immunodeficiency virus type 1 Vpr transactivator: cooperation with promoter-bound activator domains and binding to TFIIB. J Mol Biol 261, 599–606.[CrossRef]
    [Google Scholar]
  2. Agostini, I., Navarro, J. M., Bouhamdan, M., Willetts, K., Rey, F., Spire, B., Vigne, R., Pomerantz, R. & Sire, J. ( 1999; ). The HIV-1 Vpr co-activator induces a conformational change in TFIIB. FEBS Lett 450, 235–239.[CrossRef]
    [Google Scholar]
  3. Andersen, J. L. & Planelles, V. ( 2005; ). The role of Vpr in HIV-1 pathogenesis. Curr HIV Res 3, 43–51.[CrossRef]
    [Google Scholar]
  4. Andersen, J. L., Le Rouzic, E. & Planelles, V. ( 2008; ). HIV-1 Vpr: mechanisms of G2 arrest and apoptosis. Exp Mol Pathol 85, 2–10.[CrossRef]
    [Google Scholar]
  5. Anderson, J. L. & Hope, T. J. ( 2004; ). HIV accessory proteins and surviving the host cell. Curr HIV/AIDS Rep 1, 47–53.[CrossRef]
    [Google Scholar]
  6. Arunagiri, C., Macreadie, I., Hewish, D. & Azad, A. ( 1997; ). A C-terminal domain of HIV-1 accessory protein Vpr is involved in penetration, mitochondrial dysfunction and apoptosis of human CD4+ lymphocytes. Apoptosis 2, 69–76.[CrossRef]
    [Google Scholar]
  7. Ayyavoo, V., Muthumani, K., Kudchodkar, S., Zhang, D., Ramanathan, P., Dayes, N. S., Kim, J. J., Sin, J. I., Montaner, L. J. & Weiner, D. B. ( 2002; ). HIV-1 viral protein R compromises cellular function in vivo. Int Immunol 14, 13–22.[CrossRef]
    [Google Scholar]
  8. Bachand, F., Yao, X. J., Hrimech, M., Rougeau, N. & Cohen, E. ( 1999; ). Incorporation of Vpr into human immunodeficiency virus type 1 requires a direct interaction with the p6 domain of the p55 Gag precursor. J Biol Chem 274, 9083–9091.[CrossRef]
    [Google Scholar]
  9. Balasubramanyam, A., Mersmann, H., Jahoor, F., Phillips, T. M., Sekhar, R. V., Schubert, U., Brar, B., Iyer, D., Smith, E. O. & other authors ( 2007; ). Effects of transgenic expression of HIV-1 Vpr on lipid and energy metabolism in mice. Am J Physiol Endocrinol Metab 292, E40–E48.
    [Google Scholar]
  10. Basanez, G. & Zimmerberg, J. ( 2001; ). HIV and apoptosis: death and the mitochondrion. J Exp Med 193, F11–F14.[CrossRef]
    [Google Scholar]
  11. Basavapathruni, A. & Anderson, K. S. ( 2007; ). Reverse transcription of the HIV-1 pandemic. FASEB J 21, 3795–3808.[CrossRef]
    [Google Scholar]
  12. Belzile, J. P., Duisit, G., Rougeau, N., Mercier, J., Finzi, A. & Cohen, E. A. ( 2007; ). HIV-1 Vpr-mediated G2 arrest involves the DDB1–CUL4AVPRBP E3 ubiquitin ligase. PLoS Pathog 3, E85 [CrossRef]
    [Google Scholar]
  13. Benko, Z., Liang, D., Agbottah, E., Hou, J., Taricani, L., Young, P. G., Bukrinsky, M. & Zhao, R. Y. ( 2007; ). Antagonistic interaction of HIV-1 Vpr with Hsf-mediated cellular heat shock response and Hsp16 in fission yeast (Schizosaccharomyces pombe). Retrovirology 4, 16 [CrossRef]
    [Google Scholar]
  14. Berkhout, B. & de Ronde, A. ( 2004; ). APOBEC3G versus reverse transcriptase in the generation of HIV-1 drug-resistance mutations. AIDS 18, 1861–1863.[CrossRef]
    [Google Scholar]
  15. Bouhamdan, M., Benichou, S., Rey, F., Navarro, J. M., Agostini, I., Spire, B., Camonis, J., Slupphaug, G., Vigne, R. & other authors ( 1996; ). Human immunodeficiency virus type 1 Vpr protein binds to the uracil DNA glycosylase DNA repair enzyme. J Virol 70, 697–704.
    [Google Scholar]
  16. Bouhamdan, M., Xue, Y. N., Baudat, Y., Hu, B., Sire, J., Pomerantz, R. J. & Duan, L. X. ( 1998; ). Diversity of HIV-1 Vpr interactions involves usage of the WXXF motif of host cell proteins. J Biol Chem 273, 8009–8016.[CrossRef]
    [Google Scholar]
  17. Budihardjo, I., Oliver, H., Lutter, M., Lue, X. & Wang, X. ( 1999; ). Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol 15, 269–290.[CrossRef]
    [Google Scholar]
  18. Chang, L. J., Chen, C. H., Urlacher, V. & Lee, T. F. ( 2000; ). Differential apoptosis effects of primate lentiviral Vpr and Vpx in mammalian cells. J Biomed Sci 7, 322–333.[CrossRef]
    [Google Scholar]
  19. Chang, F., Re, F., Sebastian, S., Sazer, S. & Luban, J. ( 2004; ). HIV-1 Vpr induces defects in mitosis, cytokinesis, nuclear structure, and centrosomes. Mol Biol Cell 15, 1793–1801.[CrossRef]
    [Google Scholar]
  20. Chen, R., Wang, H. & Mansky, L. M. ( 2002; ). Roles of uracil–DNA glycosylase and dUTPase in virus replication. J Gen Virol 83, 2339–2345.
    [Google Scholar]
  21. Chen, R., Le Rouzic, E., Kearney, J. A., Mansky, L. M. & Benichou, S. ( 2004; ). Vpr-mediated incorporation of UNG2 into HIV-1 particles is required to modulate the virus mutation rate and for replication in macrophages. J Biol Chem 279, 28419–28425.[CrossRef]
    [Google Scholar]
  22. Conti, L., Matarrese, P., Varano, B., Gauzzi, M. C., Sato, A., Malorni, W., Belardelli, F. & Gessani, S. ( 2000; ). Dual role of the HIV-1 Vpr protein in the modulation of the apoptotic response of T cells. J Immun 165, 3293–3300.[CrossRef]
    [Google Scholar]
  23. Csikasz-Nagy, A., Battogtokh, D., Chen, K. C., Novak, B. & Tyson, J. J. ( 2006; ). Analysis of a generic model of eukaryotic cell-cycle regulation. Biophys J 90, 4361–4379.[CrossRef]
    [Google Scholar]
  24. de Noronha, C. M., Sherman, M. P., Lin, H. W., Cavrois, M. V., Moir, R. D., Goldman, R. D. & Greene, W. C. ( 2001; ). Dynamic disruptions in nuclear envelope architecture and integrity induced by HIV-1 Vpr. Science 294, 1105–1108.[CrossRef]
    [Google Scholar]
  25. Elder, R. T., Yu, M., Chen, M., Zhu, X., Yanagida, M. & Zhao, Y. ( 2001; ). HIV-1 Vpr induces cell cycle G2 arrest in fission yeast (Schizosaccharomyces pombe) through a pathway involving regulatory and catalytic subunits of PP2A and acting on both Wee1 and Cdc25. Virology 287, 359–370.[CrossRef]
    [Google Scholar]
  26. Engler, A., Stangler, T. & Willbold, D. ( 2001; ). Solution structure of human immunodeficiency virus type 1 Vpr (13–33) peptide in micelles. Eur J Biochem 268, 389–395.[CrossRef]
    [Google Scholar]
  27. Felzien, L. K., Woffendin, C., Hottiger, M. O., Subbramanian, R. A., Cohen, E. A. & Nabel, G. J. ( 1998; ). HIV transcriptional activation by the accessory protein, VPR, is mediated by the p300 co-activator. Proc Natl Acad Sci U S A 95, 5281–5286.[CrossRef]
    [Google Scholar]
  28. Gallay, P., Stitt, V., Mundy, C., Oettinger, M. & Trono, D. ( 1996; ). Role of the karyopherin pathway in human immunodeficiency virus type 1 nuclear import. J Virol 70, 1027–1032.
    [Google Scholar]
  29. Gallay, P., Hope, T., Chin, D. & Trono, D. ( 1997; ). HIV-1 infection of nondividing cells through the recognition of integrase by the importin/karyopherin pathway. Proc Natl Acad Sci U S A 94, 9825–9830.[CrossRef]
    [Google Scholar]
  30. Gao, L., Balakrishnan, M., Roques, B. P. & Bambara, R. A. ( 2007; ). Insights into the multiple roles of pausing in HIV-1 reverse transcriptase-promoted strand transfers. J Biol Chem 282, 6222–6231.
    [Google Scholar]
  31. Giaccia, A. J. & Kastan, M. B. ( 1998; ). The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev 12, 2973–2983.[CrossRef]
    [Google Scholar]
  32. Gieffers, C., Schleiffer, A. & Peters, J.-M. ( 2000; ). Cullins and cell cycle control. Protoplasma 211, 20–28.[CrossRef]
    [Google Scholar]
  33. Goh, W. C., Rogel, M. E., Kinsey, M., Michael, S. F., Fultz, P. N., Nowak, M. A., Hahn, B. H. & Emerman, M. ( 1998; ). HIV-1 Vpr increases viral expression by manipulation of the cell cycle: a mechanism for selection of Vpr in vivo. Nat Med 4, 65–71.[CrossRef]
    [Google Scholar]
  34. Goh, W. C., Manel, N. & Emerman, M. ( 2004; ). The human immunodeficiency virus Vpr protein binds Cdc25C: implications for G2 arrest. Virology 318, 337–349.[CrossRef]
    [Google Scholar]
  35. Green, D. R. ( 2000; ). Apoptotic pathways: paper wraps stone blunts scissors. Cell 102, 1–4.[CrossRef]
    [Google Scholar]
  36. He, J., Choe, S., Walker, R., Di Marzio, P., Morgan, D. O. & Landau, N. R. ( 1995; ). Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J Virol 69, 6705–6711.
    [Google Scholar]
  37. Higa, L. A. & Zhang, H. ( 2007; ). Stealing the spotlight: CUL4–DDB1 ubiquitin ligase docks WD40-repeat proteins to destroy. Cell Div 2, 5 [CrossRef]
    [Google Scholar]
  38. Hrecka, K., Gierszewska, M., Srivastava, S., Kozaczkiewicz, L., Swanson, S. K., Florens, L., Washburn, M. P. & Skowronski, J. ( 2007; ). Lentiviral Vpr usurps Cul4–DDB1[VprBP] E3 ubiquitin ligase to modulate cell cycle. Proc Natl Acad Sci U S A 104, 11778–11783.[CrossRef]
    [Google Scholar]
  39. Huang, M. B., Weeks, O., Zhao, L. J., Saltarelli, M. & Bond, V. C. ( 2000; ). Effects of extracellular human immunodeficiency virus type 1 Vpr protein in primary rat cortical cell cultures. J Neurovirol 6, 202–220.[CrossRef]
    [Google Scholar]
  40. Huard, S., Elder, R. T., Liang, D., Li, G. & Zhao, R. I. ( 2008; ). Human immunodeficiency virus type 1 Vpr induces cell cycle G2 arrest through Srk1/MK2-mediated phosphorylation of Cdc25. J Virol 82, 2904–2917.[CrossRef]
    [Google Scholar]
  41. Jacotot, E., Ravagnan, L., Loeffler, M., Ferri, K. F., Vieira, H. L., Zamzami, N., Costantini, P., Druillennec, S., Hoebeke, J. & other authors ( 2000; ). The HIV-1 viral protein R induces apoptosis via a direct effect on the mitochondrial permeability transition pore. J Exp Med 191, 33–45.[CrossRef]
    [Google Scholar]
  42. Jacotot, E., Ferri, K. F., El Hamel, C., Brenner, C., Druillennec, S., Hoebeke, J., Rustin, P., Métivier, D., Lenoir, C. & other authors ( 2001; ). Control of mitochondrial membrane permeabilization by adenine nucleotide translocator interacting with HIV-1 viral protein R and Bcl-2. J Exp Med 193, 509–519.[CrossRef]
    [Google Scholar]
  43. Jenkins, Y., McEntee, M., Weis, K. & Greene, W. C. ( 1998; ). Characterization of HIV-1 Vpr nuclear import: analysis of signals and pathways. J Cell Biol 143, 875–885.[CrossRef]
    [Google Scholar]
  44. Jin, J., Arias, E. E., Chen, J., Harper, J. W. & Walter, J. C. ( 2006; ). A family of diverse Cul4-Ddb1-interacting proteins includes Cdt2, which is required for S phase destruction of the replication factor Cdt1. Mol Cell 23, 709–721.[CrossRef]
    [Google Scholar]
  45. Jowett, J. B., Xie, Y. M. & Chen, I. S. Y. ( 1999; ). The presence of human immunodeficiency virus type 1 Vpr correlates with a decrease in the frequency of mutations in a plasmid shuttle vector. J Virol 73, 7132–7137.
    [Google Scholar]
  46. Keele, B. F., Giorgi, E. E., Salazar-Gonzalez, J. F., Decker, J. M., Pham, K. T., Salazar, M. G., Sun, C., Grayson, T., Wang, S. & other authors ( 2008; ). Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A 105, 7552–7557.[CrossRef]
    [Google Scholar]
  47. Kim, H. E., Du, F., Fang, M. & Wang, X. ( 2005; ). Formation of apoptosome is initiated by cytochrome c-induced dATP hydrolysis and subsequent nucleotide exchange on Apaf-1. Proc Natl Acad Sci U S A 102, 17545–17550.[CrossRef]
    [Google Scholar]
  48. Kino, T. & Chrousos, G. P. ( 2004; ). Human immunodeficiency virus type-1 accessory protein Vpr: a causative agent of the AIDS-related insulin resistance/lipodystrophy syndrome? Ann N Y Acad Sci 1024, 153–167.[CrossRef]
    [Google Scholar]
  49. Kino, T., Gragerov, A. & Slobodskaya, O. ( 2002; ). Human immunodeficiency virus type 1 (HIV-1) accessory protein Vpr induces transcription of the HIV-1 and glucocorticoid-responsive promoters by binding directly to p300/CBP coactivators. J Virol 76, 9724–9734.[CrossRef]
    [Google Scholar]
  50. Kino, T., Gragerov, A., Valentin, A., Tsopanomihalou, M., Ilyina-Gragerova, G., Erwin-Cohen, R., Chrousos, G. P. & Pavlakis, G. N. ( 2005; ). Vpr protein of human immunodeficiency virus type 1 binds to 14-3-3 proteins and facilitates complex formation with Cdc25C: implications for cell cycle arrest. J Virol 79, 2780–2787.[CrossRef]
    [Google Scholar]
  51. Kitayama, H., Miura, Y., Ando, Y., Hoshino, S., Ishizaka, Y. & Koyanagi, Y. ( 2008; ). Human immunodeficiency virus type 1 Vpr inhibits axonal outgrowth through induction of mitochondrial dysfunction. J Virol 82, 2528–2542.[CrossRef]
    [Google Scholar]
  52. Krylov, D. M., Nasmyth, K. & Koonin, E. V. ( 2003; ). Evolution of eukaryotic cell cycle regulation: stepwise addition of regulatory kinases and late advent of the CDKs. Curr Biol 13, 173–177.[CrossRef]
    [Google Scholar]
  53. Lavallee, C., Yao, X. J., Ladha, A., Gottlinger, H., Haseltine, W. A. & Cohen, E. A. ( 1994; ). Requirement of the Pr55gag precursor for incorporation of the Vpr product into human immunodeficiency virus type 1 viral particles. J Virol 68, 1926–1934.
    [Google Scholar]
  54. Le Rouzic, E. & Benichou, S. ( 2005; ). The Vpr protein from HIV-1: distinct roles along the viral life cycle. Retrovirology 2, 11 [CrossRef]
    [Google Scholar]
  55. Le Rouzic, E., Mousnier, A., Rustum, C., Stutz, F., Hallberg, E., Dargemont, C. & Benichou, S. ( 2002; ). Docking of HIV-1 Vpr to the nuclear envelope is mediated by the interaction with the nucleoporin hCG1. J Biol Chem 277, 45091–45098.[CrossRef]
    [Google Scholar]
  56. Li, Y., Zhang, Z., Wakefield, J. K., Kang, S. M. & Morrow, C. D. ( 1997; ). Nucleotide substitutions within U5 are critical for efficient reverse transcription of human immunodeficiency virus type 1 with a primer binding site complementary to tRNAHis. J Virol 71, 6315–6322.
    [Google Scholar]
  57. Majumder, B., Venkatachari, N. J., O'Leary, S. & Ayyavoo, V. ( 2008; ). Infection with Vpr-positive human immunodeficiency virus type 1 impairs NK cell function indirectly through cytokine dysregulation of infected target cells. J Virol 82, 7189–7200.[CrossRef]
    [Google Scholar]
  58. Mansky, L. M. ( 1996; ). The mutation rate of human immunodeficiency virus type 1 is influenced by the vpr gene. Virology 222, 391–400.[CrossRef]
    [Google Scholar]
  59. Mansky, L. M., Preveral, S., Selig, L., Benarous, R. & Benichou, S. ( 2000; ). The interaction of Vpr with uracil DNA glycosylase modulates the human immunodeficiency virus type 1 in vivo mutation rate. J Virol 74, 7039–7047.[CrossRef]
    [Google Scholar]
  60. Moon, H. S. & Yang, J. S. ( 2006; ). Role of HIV Vpr as a regulator of apoptosis and an effector on bystander cells. Mol Cells 21, 7–20.
    [Google Scholar]
  61. Müller, B., Tessmer, U., Schubert, U. & Kräusslich, H. G. ( 2000; ). Human immunodeficiency virus type 1 Vpr protein is incorporated into the virion in significantly smaller amounts than Gag and is phosphorylated in infected cells. J Virol 74, 9727–9731.[CrossRef]
    [Google Scholar]
  62. Muthumani, K., Kudchodkar, S., Papasavvas, E., Montaner, L. J., Weiner, D. B. & Ayyavoo, V. ( 2000; ). HIV-1 Vpr regulates expression of β chemokines in human primary lymphocytes and macrophages. J Leukoc Biol 68, 366–372.
    [Google Scholar]
  63. Muthumani, K., Hwang, D. S., Dayes, N. S., Kim, J. J. & Weiner, D. B. ( 2002a; ). The HIV-1 accessory gene vpr can inhibit antigen-specific immune function. DNA Cell Biol 21, 689–695.[CrossRef]
    [Google Scholar]
  64. Muthumani, K., Hwang, D. S., Desai, B. M., Zhang, D., Dayes, N. S., Green, D. R. & Weiner, D. B. ( 2002b; ). HIV-1 Vpr induces apoptosis through caspase 9 in T cells and peripheral blood mononuclear cells. J Biol Chem 277, 37820–37831.[CrossRef]
    [Google Scholar]
  65. Muthumani, K., Desai, B. M., Hwang, D. S., Choo, A. Y., Laddy, D. J., Thieu, K. P., Rao, R. G. & Weiner, D. B. ( 2004a; ). HIV-1 Vpr and anti-inflammatory activity. DNA Cell Biol 23, 239–247.[CrossRef]
    [Google Scholar]
  66. Muthumani, K., Hwang, D. S., Choo, A. Y., Mayilvahanan, S., Dayes, N. S., Thieu, K. P. & Weiner, D. B. ( 2004b; ). HIV-1 Vpr inhibits the maturation and activation of macrophages and dendritic cells in vitro. Int Immunol 17, 103–116.[CrossRef]
    [Google Scholar]
  67. Muthumani, K., Choo, A. Y., Hwang, D. S., Dayes, N. S., Chattergoon, M., Mayilvahanan, S., Thieu, K. P., Buckley, P. T., Emmanuel, J. & other authors ( 2005; ). HIV-1 viral protein-R (Vpr) protects against lethal superantigen challenge while maintaining homeostatic T cell levels in vivo. Mol Ther 12, 910–921.[CrossRef]
    [Google Scholar]
  68. Muthumani, K., Choo, A. Y., Zong, W. X., Madesh, M., Hwang, D. S., Premkumar, A., Thieu, K. P., Emmanuel, J., Kumar, S. & other authors ( 2006; ). The HIV-1 Vpr and glucocorticoid receptor complex is a gain-of-function interaction that prevents the nuclear localization of PARP-1. Nat Cell Biol 8, 170–179.[CrossRef]
    [Google Scholar]
  69. Nitahara-Kasahara, Y., Kamata, M., Yamamoto, T., Zhang, X., Miyamoto, Y., Muneta, K., Iijima, S., Yoneda, Y., Tsunetsugu-Yokota, Y. & Aida, Y. ( 2007; ). A novel nuclear import of Vpr promoted by importin α is crucial for HIV-1 replication in macrophages. J Virol 81, 5284–5293.[CrossRef]
    [Google Scholar]
  70. Pauls, E., Senserrich, J., Clotet, B. & Este, J. A. ( 2006; ). Inhibition of HIV-1 replication by RNA interference of p53 expression. J Leukoc Biol 80, 659–667.[CrossRef]
    [Google Scholar]
  71. Piller, S. C., Jans, P., Gage, P. W. & Jans, D. A. ( 1998; ). Extracellular HIV-1 virus protein R causes a large inward current and cell death in cultured hippocampal neurons: implications for AIDS pathology. Proc Natl Acad Sci U S A 95, 4595–4600.[CrossRef]
    [Google Scholar]
  72. Piller, S. C., Ewart, G. D., Jans, D. A., Gage, P. W. & Cox, G. B. ( 1999; ). The amino-terminal region of Vpr from human immunodeficiency virus type 1 forms ion channels and kills neurons. J Virol 73, 4230–4238.
    [Google Scholar]
  73. Poon, B., Chang, M. A. & Chen, I. S. Y. ( 2007; ). Vpr is required for efficient Nef expression from unintegrated HIV-1 DNA. J Virol 81, 10515–10523.[CrossRef]
    [Google Scholar]
  74. Priet, S., Navarro, J. M., Gros, N., Querat, G. & Sire, J. ( 2003; ). Functional role of HIV-1 virion-associated uracil DNA glycosylase 2 in the correction of G : U mispairs to G : C pairs. J Biol Chem 278, 4566–4571.[CrossRef]
    [Google Scholar]
  75. Ramanathan, M. P., Curley, E., III, Su, M., Chambers, J. A. & Weiner, D. B. ( 2002; ). Carboxyl terminus of hVIP/mov34 is critical for HIV-1-Vpr interaction and glucocorticoid-mediated signaling. J Biol Chem 277, 47854–47860.[CrossRef]
    [Google Scholar]
  76. Rialland, M., Sola, F. & Santocanale, C. ( 2002; ). Essential role of human CDT1 in DNA replication and chromatin licensing. J Cell Sci 115, 1435–1440.
    [Google Scholar]
  77. Rogel, M. E., Wu, L. I. & Emerman, M. ( 1995; ). The human immunodeficiency virus type 1 vpr gene prevents cell proliferation during chronic infection. J Virol 69, 882–888.
    [Google Scholar]
  78. Rom, I., Deshmane, S. L., Mukerjee, R., Khalili, K., Amini, S. & Sawaya, B. E. ( 2009; ). HIV-1 Vpr deregulates calcium secretion in neural cells. Brain Res 1275, 81–86.[CrossRef]
    [Google Scholar]
  79. Roumier, T., Vieira, H. L., Castedo, M., Ferri, K. F., Boya, P., Andreau, K., Druillennec, S., Joza, N., Penninger, J. M. & other authors ( 2002; ). The C-terminal moiety of HIV-1 Vpr induces cell death via a caspase-independent mitochondrial pathway. Cell Death Differ 9, 1212–1219.[CrossRef]
    [Google Scholar]
  80. Sawaya, B. E., Khalili, K., Mercer, W. E., Denisova, L. & Amini, S. ( 1998; ). Cooperative actions of HIV-1 Vpr and p53 modulate viral gene transcription. J Biol Chem 273, 20052–20057.[CrossRef]
    [Google Scholar]
  81. Sawaya, B. E., Khalili, K., Gordon, J., Taube, R. & Amini, S. ( 2000; ). Cooperative interaction between HIV-1 regulatory proteins Tat and Vpr modulates transcription of the viral genome. J Biol Chem 275, 35209–35214.[CrossRef]
    [Google Scholar]
  82. Schang, L. M. ( 2003; ). The cell cycle, cyclin-dependent kinases, and viral infections: new horizons and unexpected connections. Prog Cell Cycle Res 5, 103–124.
    [Google Scholar]
  83. Shrivastav, S., Kino, T., Cunningham, T., Ichijo, T., Schubert, U., Heinklein, P., Chrousos, G. P. & Kopp, J. B. ( 2008; ). Human immunodeficiency virus (HIV)-1 viral protein R suppresses transcriptional activity of peroxisome proliferator-activated receptor γ and inhibits adipocyte differentiation: implications for HIV-associated lipodystrophy. Mol Endocrinol 22, 234–247.[CrossRef]
    [Google Scholar]
  84. Somasundaran, M., Sharkey, M., Brichacek, B., Luzuriaga, K., Emerman, M., Sullivan, J. L. & Stevenson, M. ( 2002; ). Evidence for a cytopathogenicity determinant in HIV-1 Vpr. Proc Natl Acad Sci U S A 99, 9503–9508.[CrossRef]
    [Google Scholar]
  85. Srinivasan, A., Ayyavoo, V., Mahalingam, S., Kannan, A., Boyd, A., Datta, D., Kalyanaraman, V. S., Cristillo, A., Collman, R. G. & other authors ( 2008; ). A comprehensive analysis of the naturally occurring polymorphisms in HIV-1 Vpr: potential impact on CTL epitopes. Virol J 5, 99 [CrossRef]
    [Google Scholar]
  86. Stark, L. A. & Hay, R. T. ( 1998; ). Human immunodeficiency virus type 1 (HIV-1) viral protein R (Vpr) interacts with Lys-tRNA synthetase: implications for priming of HIV-1 reverse transcription. J Virol 72, 3037–3044.
    [Google Scholar]
  87. Stewart, S. A., Poon, B., Jowett, J. B. M., Xie, Y. & Chen, I. S. Y. ( 1999; ). Lentiviral delivery of HIV-1 Vpr protein induces apoptosis in transformed cells. Proc Natl Acad Sci U S A 96, 12039–12043.[CrossRef]
    [Google Scholar]
  88. Sun, Y., Pinchuk, L. M., Agy, M. B. & Clark, E. A. ( 1997; ). Nuclear import of HIV-1 DNA in resting CD4+ T cells requires a cyclosporin A-sensitive pathway. J Immun 158, 512–517.
    [Google Scholar]
  89. Suzuki, T., Yamamoto, N., Nonaka, M., Hashimoto, Y., Matsuda, G., Takeshima, S. N., Matsuyama, M., Igarashi, T., Miura, T. & other authors ( 2009; ). Inhibition of human immunodeficiency virus type 1 (HIV-1) nuclear import via Vpr–importin α interactions as a novel HIV-1 therapy. Biochem Biophys Res Commun 380, 838–843.[CrossRef]
    [Google Scholar]
  90. Tungaturthi, P. K., Sawaya, B. E., Ayyavoo, V., Murali, R. & Srinivasan, A. ( 2004; ). HIV-1 Vpr: genetic diversity and functional features from the perspective of structure. DNA Cell Biol 23, 207–222.[CrossRef]
    [Google Scholar]
  91. Vafiadaki, E., Sanoudou, D., Arvanitis, D. A., Catino, D. H., Kranias, E. G. & Kontrogianni-Konstantopoulos, A. ( 2006; ). Phospholamban interacts with HAX-1, a mitochondrial protein with anti-apoptotic function. J Mol Biol 367, 65–79.
    [Google Scholar]
  92. Vafiadaki, E., Arvanitis, D. A., Pagakis, S. N., Papalouka, V., Sanoudou, D., Kontrogianni-Konstantopoulos, A. & Kranias, E. G. ( 2009; ). The anti-apoptotic protein HAX-1 interacts with SERCA2 and regulates its protein levels to promote cell survival. Mol Biol Cell 20, 306–318.[CrossRef]
    [Google Scholar]
  93. Varin, A., Decrion, A. Z., Sabbah, E., Quivy, V., Sire, J., Lint, C. V., Roques, B. P., Aggarwal, B. B. & Herbein, G. ( 2005; ). Synthetic Vpr protein activates activator protein-1, c-jun N-terminal kinase, and NF-κB and stimulates HIV-1 transcription in promonocytic cells and primary macrophages. J Biol Chem 280, 42557–42567.[CrossRef]
    [Google Scholar]
  94. Vodicka, M. A., Koepp, D. M., Silver, P. M. & Emerman, M. ( 1998; ). HIV-1 Vpr interacts with the nuclear transport pathway to promote macrophage infection. Genes Dev 12, 175–185.[CrossRef]
    [Google Scholar]
  95. Wang, L., Mukherjee, S., Jia, F., Narayan, O. & Zhao, L. J. ( 1995; ). Interaction of virion protein Vpr of human immunodeficiency virus type 1 with cellular transcription factor Sp1 and trans-activation of viral long terminal repeat. J Biol Chem 270, 25564–25569.[CrossRef]
    [Google Scholar]
  96. Wang, L., Mukherjee, S., Narayan, O. & Zhao, L. J. ( 1996; ). Characterization of a leucine-zipper-like domain in Vpr protein of human immunodeficiency virus type 1. Gene 178, 7–13.[CrossRef]
    [Google Scholar]
  97. Wang, J., Shackelford, J. M., Selliah, N., Shivers, D. K., O'Neill, E., Garcia, J. V., Muthumani, K., Weiner, D., Yu, X. F. & other authors ( 2008; ). The HIV-1 Vif protein mediates degradation of Vpr and reduces Vpr-induced cell cycle arrest. DNA Cell Biol 27, 267–277.[CrossRef]
    [Google Scholar]
  98. Warbrick, E. & Fantes, P. A. ( 1988; ). A conserved eukaryotic cell cycle control. Bioessays 8, 202–204.[CrossRef]
    [Google Scholar]
  99. Wen, X., Duus, K. M., Friedrich, T. D. & de Noronha, C. M. C. ( 2007; ). The HIV1 protein Vpr acts to promote G2 cell cycle arrest by engaging a DDB1 and cullin4A-containing ubiquitin ligase complex using VprBP/DCAF1 as an adaptor. J Biol Chem 282, 27046–27057.[CrossRef]
    [Google Scholar]
  100. Withers-Ward, E. S., Jowett, J. B. M., Stewart, S. A., Xie, Y. M., Garfinkel, A., Shibagaki, Y., Chow, S. A., Shah, N., Hanaoka, F. & other authors ( 1997; ). Human immunodeficiency virus type 1 Vpr interacts with HHR23A, a cellular protein implicated in nucleotide excision DNA repair. J Virol 71, 9732–9742.
    [Google Scholar]
  101. Xiao, Y., Chen, G., Richard, J., Rougeau, N., Li, H., Seidah, N. G. & Cohen, E. A. ( 2008; ). Cell-surface processing of extracellular human immunodeficiency virus type 1 Vpr by proprotein convertases. Virology 372, 384–397.[CrossRef]
    [Google Scholar]
  102. Yao, X. J., Lemay, J., Rougeau, N., Clement, M., Kurtz, S., Belhumeur, P. & Cohen, E. A. ( 2002; ). Genetic selection of peptide inhibitors of human immunodeficiency virus type 1 Vpr. J Biol Chem 277, 48816–48826.[CrossRef]
    [Google Scholar]
  103. Yedavalli, V. S. R. K., Shih, H. M., Chiang, Y. P., Lu, C. Y., Chang, L. Y., Chen, M. Y., Chuang, C. Y., Dayton, A. I., Jeang, K. T. & Huang, L. M. ( 2005; ). Human immunodeficiency virus type 1 Vpr interacts with antiapoptotic mitochondrial protein HAX-1. J Virol 79, 13735–13746.[CrossRef]
    [Google Scholar]
  104. Zeitler, B. & Weis, K. ( 2004; ). The FG-repeat asymmetry of the nuclear pore complex is dispensable for bulk nucleocytoplasmic transport in vivo. J Cell Biol 167, 583–590.[CrossRef]
    [Google Scholar]
  105. Zhao, R. Y., Bukrinsky, M. & Elder, R. T. ( 2005; ). HIV-1 viral protein R (Vpr) & host cellular responses. Indian J Med Res 121, 270–286.
    [Google Scholar]
  106. Zhu, Y., Gelbard, H. A., Roshal, M., Pursell, S., Jamieson, B. D. & Planelles, V. ( 2001; ). Comparison of cell cycle arrest, transactivation, and apoptosis induced by the simian immunodeficiency virus SIVagm and human immunodeficiency virus type 1 vpr genes. J Virol 75, 3791–3801.[CrossRef]
    [Google Scholar]
  107. Zhu, Y., Roshal, M., Li, F., Blackett, J. & Planelles, V. ( 2003; ). Upregulation of survivin by HIV-1 Vpr. Apoptosis 8, 71–79.[CrossRef]
    [Google Scholar]
  108. Zou, H., Yang, R., Hao, J., Wang, J., Sun, C., Fesik, S. W., Wu, J. C., Tomaselli, K. J. & Armstrong, R. C. ( 2003; ). Regulation of the Apaf-1/caspase-9 apoptosome by caspase-3 and XIAP. J Biol Chem 278, 8091–8098.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.011726-0
Loading
/content/journal/jgv/10.1099/vir.0.011726-0
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error